EHA 2024 - Prof John Gribben speaks to Deborah Henderson about CLL Clinical Trials
John Gribben - American Society of Hematology (ASH) conference
John Gribben - CAR-T Therapy
ASH 2019 Interview - Prof John Gribben and Deborah Sims - Overview of CLL treatment
Professor John G. Gribben: iwCLL 2017
John Gribben’s ASH 2019 CLL and lymphoma highlights
Prof. John Gribben describes Deborah's clinical trial: venetoclax (ABT-199) plus obinutuzumab
Professor John Gribben - Treating patients with chronic lymphocytic leukaemia (CLL)
Prof. John Gribben | ASH 2017 | Major advances in immunotherapies during ASH 2017
CAR-T vs bispecific antibodies for lymphoma
Prof John Gribben: Highlights of CLL - ICML 2017
Exciting explosion of new drugs in CLL
O Danny Boy arr. by John Gribben
Where will leukemia research go next?
Danny Boy - arrang. John Gribben - piano
Key themes at EHA 2020
Lymphoma microenvironment: biology and therapy (part 1/3)
ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 1)
ASH 2019 Interview - Prof John Gribben - precision medicine & genetic testing
BCR inhibitors improving CLL patient outcomes